Glimepiride

93479-97-1

490.62

DMSO : 33.33 mg/mL (67.93 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble)

Others

Glimepiride (Glimperide) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED₅₀ of 182 ug/kg. IC50 & Target: DPP4^[1]. In Vivo: Glimepiride (Glimperide) is a new sulfonylurea. After oral administration of Hoe 490 to rabbits, blood glucose was lowered 3.5 times more than after glibenclamide (HB 419) and after intravenous administration, 2.5 times more^[1]. Glimepiride (Glimperide) decreased extracellular Abeta40 and Abeta42 levels. glimepiride may serve as a promising drug for the treatment of AD associated with diabetes^[2]. Glimepiride (Glimperide) was generally associated with lower risk of hypoglycemia and less weight gain compared to other sulfonylureas. Glimepiride (Glimperide) use may be safer in patients with cardiovascular disease because of its lack of detrimental effects on ischemic preconditioning^[3].